peter lees

Emeritus Professor

Royal Veterinary College

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Peter Lees is an Emeritus Professor at the Royal Veterinary College in the UK. His research primarily focuses on pharmacokinetics and pharmacodynamics of antimicrobial drugs in veterinary medicine, with recent publications addressing topics such as dosage efficacy in pigs and the clinical applications of COX-2 inhibitors. He has contributed to discussions on bioequivalence in pharmaceuticals and has a notable history of research on antimicrobial drugs in animals.

Articles (8)

Year:

2025

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Ludovic Pelligand

Royal Veterinary College

UNITED KINGDOM

View details

Didier Concordet

Professor

Ecole nationale vétérinaire de Toulouse

FRANCE

View details

Siska Croubels

Full professor

Universiteit Gent

BELGIUM

View details

Jonathan Elliott

Professor of Veterinary Clinical Pharmacology

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

peter lees

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Pharmacokinetic–Pharmacodynamic Cutoff Values for Doxycycline in Pigs to Support the Establishment of Clinical Breakpoints for Antimicrobial Susceptibility Testing

Pharmacology, safety, efficacy and clinical uses of the COX‐2 inhibitor robenacoxib

A history of antimicrobial drugs in animals: Evolution and revolution

The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal

Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Authors’ Reply to Yu et al.: “Levothyrox<sup>®</sup> New and Old Formulations: Are They Switchable for Millions of Patients?”

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Collaborators (4)

Ludovic Pelligand

Didier Concordet

Siska Croubels

Jonathan Elliott

Make your next move.